Allovir Stock Insiders

ALVR
 Stock
  

USD 7.34  0.11  1.48%   

Allovir employes about 107 people. The company is managed by 12 executives with total tenure of roughly 132 years, averaging almost 11.0 years of service per executive having 8.92 employees per reported executive. Discussion of Allovir management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Allovir future performance.
Please continue to Trending Equities.
  
  Assaf Katan  CEO
Acting President and CEO
  Amnon Yacoby  Chairman
Independent Chairman of the Board
  Zeev Farkash  President
Executive Vice President - Sales

Allovir Management Team Effectiveness

Allovir has return on total asset (ROA) of (44.81) % which means that it has lost $44.81 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (83.35) %, meaning that it created substantial loss on money invested by shareholders. Allovir management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Allovir Workforce Comparison

Allovir is rated third in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 14,922. Allovir maintains roughly 107 in number of employees contributing less than 1% to stocks in Biotechnology industry.

Allovir Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allovir insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allovir's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Allovir insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Beek Jeroen B over a week ago via Macroaxis 
Sale by Van Beek Jeroen B of 16074 shares of Allovir
Van Beek Jeroen B over a week ago via Macroaxis 
Sale by Van Beek Jeroen B of 36592 shares of Allovir
Van Beek Jeroen B over two weeks ago via Macroaxis 
Sale by Van Beek Jeroen B of 299 shares of Allovir
Van Beek Jeroen B over a month ago via Macroaxis 
Sale by Van Beek Jeroen B of 1070 shares of Allovir
Van Beek Jeroen B over a month ago via Macroaxis 
Sale by Van Beek Jeroen B of 1070 shares of Allovir
Hallal David over a month ago via Macroaxis 
Allovir exotic insider transaction detected
Van Beek Jeroen B over two months ago via Macroaxis 
Sale by Van Beek Jeroen B of 493 shares of Allovir
Brainard Diana over three months ago via Macroaxis 
Sale by Brainard Diana of 4564 shares of Allovir

Allovir Benchmark Summation

The output start index for this execution was nine with a total number of output elements of fifty-two. The Lowest and highest values over a specified period plots line showing minimum and maximum value of Allovir price series.
.

Allovir Notable Stakeholders

An Allovir stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Allovir often face trade-offs trying to please all of them. Allovir's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Allovir's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Assaf Katan - Acting President and CEOProfile
Amnon Yacoby - Independent Chairman of the BoardProfile
Zeev Farkash - Executive Vice President - SalesProfile
Moshe Fourier - Executive Vice President-R&DProfile
Nir Golan - Executive Vice PresidentProfile
Ziv Eizenberg - Executive Vice President-Human ResourcesProfile
Leor Porat - Executive Vice President General CounselProfile
Avi Stern - CFOProfile
Mati Wax - CTOProfile
Doron Inbar - Non-Executive Independent DirectorProfile
Raphael Amit - External DirectorProfile
Tali Aben - Non-Executive Independent DirectorProfile

About Allovir Management Performance

The success or failure of an entity such as Allovir often depends on how effective the management is. Allovir management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Allovir management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Allovir management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people.
The data published in Allovir's official financial statements usually reflect Allovir's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Allovir. For example, before you start analyzing numbers published by Allovir accountants, it's critical to develop an understanding of what Allovir's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Allovir's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Allovir's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Allovir's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Allovir. Please utilize our Beneish M Score to check the likelihood of Allovir's management to manipulate its earnings.

Allovir Workforce Analysis

Traditionally, organizations such as Allovir use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Allovir within its industry.

Allovir Manpower Efficiency

Return on Allovir Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.8 M
Net Loss Per Executive16 M
Working Capital Per Employee78.5 K
Working Capital Per Executive699.8 K
Please continue to Trending Equities. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
683.8 M
Return On Assets
(0.38) 
Return On Equity
(0.72) 
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.